Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.

Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Jänne PA.

Cancer Immunol Res. 2018 Sep 21. doi: 10.1158/2326-6066.CIR-18-0193. [Epub ahead of print]

PMID:
30242021
2.

Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.

Luster TA, Mukherjee I, Carrell JA, Cho YH, Gill J, Kelly L, Garcia A, Ward C, Oh L, Ullrich SJ, Migone TS, Humphreys R.

PLoS One. 2012;7(10):e47361. doi: 10.1371/journal.pone.0047361. Epub 2012 Oct 9.

3.

Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.

Mohamedali KA, Niu G, Luster TA, Thorpe PE, Gao H, Chen X, Rosenblum MG.

Biochem Pharmacol. 2012 Dec 1;84(11):1534-40. doi: 10.1016/j.bcp.2012.09.017. Epub 2012 Sep 26.

4.

Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma.

He J, Yin Y, Luster TA, Watkins L, Thorpe PE.

Clin Cancer Res. 2009 Nov 15;15(22):6871-80. doi: 10.1158/1078-0432.CCR-09-1499. Epub 2009 Nov 3.

5.

Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.

Fox NL, Humphreys R, Luster TA, Klein J, Gallant G.

Expert Opin Biol Ther. 2010 Jan;10(1):1-18. doi: 10.1517/14712590903319656. Review.

PMID:
19857186
6.

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.

Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.

Mol Cancer Ther. 2009 Feb;8(2):292-302. doi: 10.1158/1535-7163.MCT-08-0918. Epub 2009 Jan 27.

7.
8.

Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells.

Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, Thorpe PE.

J Biol Chem. 2006 Oct 6;281(40):29863-71. Epub 2006 Aug 10.

9.

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.

Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA.

Int J Cancer. 2006 May 15;118(10):2639-43.

10.

The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG.

Neoplasia. 2005 May;7(5):486-96.

11.

Distal enhancer of the mouse FGF-4 gene and its human counterpart exhibit differential activity: critical role of a GT box.

Boer B, Luster TA, Bernadt C, Rizzino A.

Mol Reprod Dev. 2005 Jul;71(3):263-74.

PMID:
15803454
12.
13.

Transcriptional regulation of the transforming growth factor-beta2 gene in glioblastoma cells.

Kingsley-Kallesen M, Luster TA, Rizzino A.

In Vitro Cell Dev Biol Anim. 2001 Nov-Dec;37(10):684-90.

PMID:
11776974
14.

Effects of B-Myb on gene transcription: phosphorylation-dependent activity ans acetylation by p300.

Johnson LR, Johnson TK, Desler M, Luster TA, Nowling T, Lewis RE, Rizzino A.

J Biol Chem. 2002 Feb 8;277(6):4088-97. Epub 2001 Dec 3.

15.

Effects of three Sp1 motifs on the transcription of the FGF-4 gene.

Luster TA, Johnson LR, Nowling TK, Lamb KA, Philipsen S, Rizzino A.

Mol Reprod Dev. 2000 Sep;57(1):4-15.

PMID:
10954851

Supplemental Content

Loading ...
Support Center